Skip to content

Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.

A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02342340
Acronym
BBB-2014
Enrollment
8
Registered
2015-01-19
Start date
2015-01-31
Completion date
2016-02-29
Last updated
2016-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Beans, Lentils, Bioavailability, Phytochemical Absorption

Brief summary

This is a single site, blinded, randomized, controlled study designed to examine phytochemical absorption, metabolism and excretion, as well as vascular health and satiety, after ingestion of 4 different bean varieties (pinto, navy, red kidney, black). Eligible participants will attend 6 in-person clinic visits for comparative testing of the 4 bean varieties versus lentils and rice.

Detailed description

This is a single site, blinded, randomized, controlled study designed to examine phytochemical absorption, metabolism and excretion, as well as vascular health and satiety, after ingestion of 4 different bean varieties (pinto, navy, red kidney, black). Recruitment will consist of a total of 8 volunteers. Volunteers will be recruited through advertisement from the local community. The study will be conducted at the I.H. Asper Clinical Research Institute,located at the St. Boniface Hospital. Participants will be asked to provide written informed consent prior to participation in the study. Participants who have provided written consent will be asked to attend an in-patient visit to provide a fasting blood sample. Should the participant be eligible to participate, they will be scheduled for six study visits to assess the bioavailability, metabolism and excretion of phytochemicals present in beans compared to lentils and white rice. Uptake, metabolism and excretion of phytochemicals present in different varieties of beans during acute phase testing in healthy individuals will be examined. Possible relationships between phytochemical composition of the beans, arterial function and satiety will be investigated as the secondary objective.

Interventions

OTHERBlack Beans (cooked)

One time consumption of 3/4 cup of cooked black beans.

OTHERPinto Beans (cooked

One time consumption of 3/4 cup of cooked pinto beans.

OTHERNavy Beans (cooked)

One time consumption of 3/4 cup of cooked navy beans.

OTHERRed Kidney Beans (cooked)

One time consumption of 3/4 cup of cooked red kidney beans.

OTHERLentils (cooked)

One time consumption of 3/4 cup of cooked lentils.

One time consumption of 3/4 cup of cooked white rice.

Sponsors

Manitoba Pulse Growers
CollaboratorOTHER
Dr. Peter Zahradka
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Males or females, ≥18 and ≤50 years; 2. Normal blood lipid profile, creatinine ≥7 units/L and ≤56 units/L, alanine aminotransferase (ALT) ≥0.7 mg/dL and ≤1.3 mg/dL for men and ≥0.6 mg/dL and ≤1.1 mg/dL for women, and glycated hemoglobin \<6%; 3. Blood pressure \<140/90 4. Body mass index (BMI) ≥20 and \<30; 5. Stable regime for the past 3 months if taking vitamin and mineral/dietary/ herbal supplements; 6. Agree not to eat beans or bean-based foods, lentils or lentil-based foods, or consume isoflavone supplements while participating in this study; 7. Willing to comply with the protocol requirements; 8. Willing to provide informed consent.

Exclusion criteria

1. Allergies to beans, bean flour or bean products, lentils or rice; 2. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment; 3. Taking any prescribed medication in the last 3 months (with the exception of birth control) or supplements that affect gastrointestinal function in the last 3 months; 4. Weight loss of ≥3 kg of body weight within the 6 months prior to enrolling in the study; 5. Current (within the last month) bacterial, viral or fungal infection, or over-the-counter medication within the past 72 hours; 6. Pregnant or lactating; 7. Unable to obtain blood samples at the screening visit or the first study visit.

Design outcomes

Primary

MeasureTime frameDescription
Composite measure of Absorption, Metabolism and Excretion of PhytochemicalsTimepoint 0 (prior to consumption), 0.5, 1.0, 1.5, 2, 4 and 6 hours post consumptionBlood and urine samples will be analyzed using a differential analysis for metabolites (p\<0.01 and fold changes ≥ 2) which will be achieved via principle component analysis (PCA), and partial least square (PLS).

Secondary

MeasureTime frameDescription
Changes in parameters of arterial stiffness through pulse wave analysis (PWA)Time points 0 (prior to consumption) and 2 and 6 hours post consumption.A measure of changes in arterial stiffness as assessed via pulse wave analysis (PWA) using a Mobil-O-Graph PWA Monitor prior to consumption, at 2 hours and 6 hours post-consumption.
Satiety Questionnaire5 hours after consumption of study productParticipants will complete a Satiety Questionnaire 5 hours after consumption of the study product.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026